Vitestro closed a $70 million Series B to accelerate clinical and commercial rollout of its Aletta Autonomous Robotic Phlebotomy Device (ARPD). The Netherlands-based medical robotics developer said the funds will refine imaging, robotics and AI integration, expand clinical studies and readiness for the FDA De Novo regulatory pathway. CEO and co‑founder Toon Overbeeke framed the round as validation of the company’s mission to standardize high‑volume blood collection. Vitestro positions Aletta to address staffing shortages, variability in venous access and throughput constraints across outpatient and high‑volume diagnostic settings. The company plans a phased market rollout, starting in Europe and advancing toward the U.S., while building manufacturing and commercial infrastructure to support large‑scale adoption.